FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/590,678	ATTY. DOCKET NO.: B0192.70065US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 4, 2007	CONFIRMATION NO.: 2839
	APPLICANT: Karlsen et al	
Sheet 1 of 3	GROUP ART UNIT: 1637	EXAMINER: Angela Marie Bertagna

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A5	5,506,105		Haydock	04-09-1996
	A6	5,580,970		Hendricks et al.	12-03-1996
	A7	5,639,871		Bauer et al.	06-17-1997
	A8	2005-0118568		Karlsen	06-02-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B4	EP	0 243 221	A1	Institut Pasteur	10-28-1987	
	B5	EP	0 373 352	A2	Behringwerke Aktiengesellschaft	06-20-1990	
	B6	EP	0 662 518	A2	Amoco Corporation	07-12-1995	
	B7	EP	0 774 518	A2	Gen-Probe Incorporated	05-21-1997	
	B8	WO	90/02821	A1	Cetus Corporation	03-22-1990	
	B9	WO	94/26934	A2	Baxter Diagnostics Inc.	11-24-1994	
	B10	WO	99/29890	A2	Digene Corporation	06-17-1999	
	B11	WO	00/00638	A2	AKZO Nobel	01-06-2000	
	B12	WO	01/73135	A2	Biosearch International PTY. LTD.	10-04-2001	
	B13	WO	02/08460	A2	Norchip AS	01-31-2002	
	B14	WO	03/057914	A2	Norchip AS	07-17-2003	
	B15	WO	03/057927	A2	Norchip AS	07-17-2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C11	[No Author Listed] HPV sequence database, Online! Los Alamos National Laboratory; 09-1997, Los Alamos National Laboratory; Human papilloma viruses 1997 compendium. E6-10 – E6-24.	
	C12	ANDERSON et al., Human papillomavirus and cervical cancer. Clin Microbiol Newslett. 2002 Aug 1;24(15):113.	
	C13	BOSCH et al., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995 Jun 7;87(11):796-802.	
	C14	CLIFFORD et al., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 Jan 13;88(1):63-73.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/590,678	ATTY. DOCKET NO.: B0192.70065US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 4, 2007	CONFIRMATION NO.: 2839
	APPLICANT: Karlsen et al	
Sheet 2 of 3	GROUP ART UNIT: 1637	EXAMINER: Angela Marie Bertagna

	C15	CORNELISSEN et al., Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas. J Gen Virol. 1990 May;71 (Pt 5):1243-6.	
	C16	COUTLEE et al., Detection of transcripts of human papillomaviruses 16 and 18 in cancer-derived cell lines and cervical biopsies by enzyme immunoassay for DNA-RNA hybrids following solution hybridization. J Clin Microbiol. 1991 May;29(5):968-74.	
	C17	CUSCHIERI et al., Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. J Med Virol. 2004 May;73(1):65-70.	
	C18	DUENSING et al., Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004 Mar 20;109(2):157-62.	
	C19	IWASAWA et al., Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer. 1996 Jun 1;77(11):2275-9.	
	C20	JEON et al., Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol. 1995 May;69(5):2989-97.	
	C21	KADO et al., Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. Gynecol Oncol. 2001 Apr;81(1):47-52.	
	C22	KARLSEN et al., Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol. 1996 Sep;34(9):2095-100.	
	C23	KLAES et al., Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999 Dec 15;59(24):6132-6.	
	C24	KRAUS et al., Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer. 2004 Apr 5;90(7):1407-13.	
	C25	KRAUS et al., Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006 Apr;44(4):1310-7.	
	C26	LIE et al., DNA versus RNA based methods for HPV testing in Norway. Evaluation of Hybrid Capture II and PreTesct HPV-Proofer, a validation study. 21st International Papillomavirus Conference, 20-26 February, Mexico City, Mexico.	
	C27	MCNICOL et al., Expression of human papillomavirus type 16 E6-E7 open reading frame varies quantitatively in biopsy tissue from different grades of cervical intraepithelial neoplasia. J Clin Microbiol. 1995 May;33(5):1169-73.	
	C28	MOLDEN et al., Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72.	
	C29	MOLDEN et al., Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol. 2006 Jan;100(1):95-100. Epub 2005 Sep 8.	
	C30	MUNOZ et al., Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278-85.	
	C31	PIM et al., Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene. 1997 Jul 17;15(3):257-64.	
	C32	SCHNEIDER-GADICKE et al., Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 1986 Sep;5(9):2285-92.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/590,678	ATTY. DOCKET NO.: B0192.70065US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: June 4, 2007	CONFIRMATION NO.: 2839
				APPLICANT: Karlsen et al	
Sheet	3	of	3	GROUP ART UNIT: 1637	EXAMINER: Angela Marie Bertagna

	C33	SOTLAR et al., Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol. 2004 Sep;74(1):107-16.	
	C34	VAN DEN BRULE et al., Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer. 1991 May 30;48(3):404-8.	
	C35	VON KNEBEL DOEBERITZ, New molecular tools for efficient screening of cervical cancer. Dis Markers. 2001;17(3):123-8.	
	C36	WALBOOMERS et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.	
	C37	WU et al., Detection of dengue viral RNA using a nucleic acid sequence-based amplification assay. J Clin Microbiol. 2001 Aug;39(8):2794-8.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.